Education
About Us
Working with TipRanks
Follow Us
MiNK Therapeutics (INKT)
NASDAQ:INKT
INKT Stock Chart & Stats
$12.54
-$0.11(-11.96%)
At close: 4:00 PM EST
$12.54
-$0.11(-11.96%)
Day’s Range― - ―
52-Week Range$6.10 - $76.00
Previous CloseN/A
Volume98.55K
Average Volume (3M)39.56K
Market Cap
$58.86M
Enterprise Value$50.07M
Total Cash (Recent Filing)$14.28M
Total Debt (Recent Filing)$5.73M
Price to Earnings (P/E)―
Beta-0.08
Next Earnings
Mar 24, 2026EPS Estimate
-0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding4,694,155
10 Day Avg. Volume31,712
30 Day Avg. Volume39,559
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-1.33
Price to Sales (P/S)0.00
P/FCF Ratio-2.73
Enterprise Value/Market Cap0.85
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-254.12
Enterprise Value/Ebitda-4.12
Forecast
1Y Price Target
$35.00Price Target Upside179.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development ExpansionMiNK plans multiple Phase 2 programs of agenT-797 across graft-versus-host disease, severe pulmonary disease, germ cell tumors, and solid tumors, expanding potential indication breadth and future revenue opportunities.
External Funding StrategyPlanned externally funded trials and potential investigator-sponsored trial models reduce MiNK's capital needs and can accelerate trial initiation without large incremental balance-sheet pressure.
Safety Profile And Differentiated MechanismAgenT-797 has shown a favorable safety profile with no high-grade neurotoxicity or severe cytokine release events and demonstrates a unique dual killing mechanism that may differentiate it from existing cell therapies.
Bears Say
Commercial CompetitionStronger-than-expected competition from approved or late-stage therapies could limit potential market share and pressure pricing if agenT-797 achieves commercialization.
Limited Early Efficacy DataA promising overall survival signal observed in a very small combination cohort of six patients requires confirmation in larger trials, creating uncertainty about the durability and generalizability of the efficacy.
Safety Risk UncertaintyEmergent safety signals in any clinical or preclinical program could force additional monitoring, trial modifications, or regulatory delays, increasing development risk.
MiNK Therapeutics News
INKT FAQ
What was MiNK Therapeutics’s price range in the past 12 months?
MiNK Therapeutics lowest stock price was $6.10 and its highest was $76.00 in the past 12 months.
What is MiNK Therapeutics’s market cap?
MiNK Therapeutics’s market cap is $58.86M.
When is MiNK Therapeutics’s upcoming earnings report date?
MiNK Therapeutics’s upcoming earnings report date is Mar 24, 2026 which is in 53 days.
How were MiNK Therapeutics’s earnings last quarter?
MiNK Therapeutics released its earnings results on Nov 14, 2025. The company reported -$0.65 earnings per share for the quarter, beating the consensus estimate of -$0.855 by $0.205.
Is MiNK Therapeutics overvalued?
According to Wall Street analysts MiNK Therapeutics’s price is currently Undervalued.
Does MiNK Therapeutics pay dividends?
MiNK Therapeutics does not currently pay dividends.
What is MiNK Therapeutics’s EPS estimate?
MiNK Therapeutics’s EPS estimate is -0.68.
How many shares outstanding does MiNK Therapeutics have?
MiNK Therapeutics has 4,694,155 shares outstanding.
What happened to MiNK Therapeutics’s price movement after its last earnings report?
MiNK Therapeutics reported an EPS of -$0.65 in its last earnings report, beating expectations of -$0.855. Following the earnings report the stock price went down -3.555%.
Which hedge fund is a major shareholder of MiNK Therapeutics?
Currently, no hedge funds are holding shares in INKT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MiNK Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.00 (179.11% Upside)
$35.00 (179.11% Upside)
Hedge Fund Trend
Decreased
By 3.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
108.86%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-75.93%
Trailing 12-Months
Company Description
MiNK Therapeutics
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
INKT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for MiNK Therapeutics was predominantly positive, highlighting significant clinical trial successes, strategic partnerships, and advancements in manufacturing capabilities. While there was an increase in net loss, the company's financial strategy and strong leadership suggest a positive outlook for future growth.View all INKT earnings summariesINKT Stock 12 Month Forecast
Average Price Target
$35.00
▲(179.11% Upside)
Technical Analysis
Ownership Overview
4.88% Insiders
0.76% Mutual Funds
<0.01% Other Institutional Investors
93.10% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---